Beyond reductions in heart failure hospitalization, recent adjudicated meta-analyses of randomized trials suggest that empagliflozin and dapagliflozin are associated with a reduced risk of sudden cardiac death across cardio-renal-metabolic populations, including heart failure cohorts, extending the spectrum of cardiovascular benefits attributed to SGLT2 inhibition [89]. This evidence concerns the gene SLC5A2 and heart failure.